Key result
The doxorubicin analog MRA-CN was approximately 1000 times more potent against human carcinomas in vitro without an increase in cardiotoxicity compared to doxorubicin.
Why the study?
Does MRA-CN improve antitumor potency without increasing cardiotoxicity compared to doxorubicin in preclinical models?
Population
Human ovarian and breast carcinomas in vitro, fetal mouse heart cultures, and human sarcoma cell line MES-SA
Comparison
3'-deamino-3'-doxorubicin vs Doxorubicin
Design
Preclinical
Authors
Loading...
Hypothesis-generating for MRA-CN as a less cardiotoxic anthracycline; leaves open clinical translation of dissociated potency and cardiotoxicity.
Does MRA-CN improve antitumor potency without increasing cardiotoxicity compared to doxorubicin in preclinical models?
The doxorubicin analog MRA-CN dissociates antitumor efficacy from cardiotoxicity in preclinical models, offering a potentially safer anthracycline alternative.
Šikić et al. (1985) studied Human ovarian and breast carcinomas. 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin (MRA-CN) vs. Doxorubicin was evaluated on Antitumor potency and cardiotoxicity. The doxorubicin analog MRA-CN was approximately 1000 times more potent against human carcinomas in vitro without an increase in cardiotoxicity compared to doxorubicin.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: